LANDSVIRKJUN
Landsvirkjun, the National Power Company of Iceland, and Advania have signed a power purchase agreement for the supply of energy to Advania’s Fitjar data centre in the southwest of Iceland. The energy will be supplied by the end of 2016 according to the agreement, which will enable Advania to continue to expand their data center operations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161214005221/en/
Landsvirkjun will supply the energy through its current power station network. The company has supported the growth of the data center industry in recent years in Iceland by offering energy from 100% renewable resources.
Hörður Arnarson, CEO of Landsvirkjun:
"Advania is a welcome addition to Landsvirkjun’s client base. The conditions in Iceland are ideal for data center operations and Landsvirkjun has in recent years actively promoted Iceland as a preferred location for data centers. The successful growth of Advania and other data centers in Iceland is based on favourable, long-term, secure energy contracts, a competitive environment and the cooperation of stakeholders within the industry in Iceland."
Gestur G. Gestsson, CEO of Advania:
"The scope of Advania’s operations, within the data center market, has grown tremendously in recent years and large-scale projects are in the pipeline in the coming months. Access to energy is a key factor in the operation of data centers and we are therefore greatly pleased by this agreement with Landsvirkjun. We believe That Landsvirkjun will strengthen our ability to service more global clients in the future. "
Advania is a leading Nordic IT company with operations in Iceland, Sweden and Norway. The company has around 1000 employees, working from 20 different stations of operation. Advania operates the Steinhella Data Center in Hafnarfjordur and the Fitjar Data Center in Reykjanesbær. The agreement will allow the company to further grow its data center operations and add to its client base.
Landsvirkjun generates 100% of its power from renewable resources. The company owns and operates 16 power stations, including 14 hydropower stations and two geothermal stations as well as two wind turbines. Landsvirkjun is currently constructing a geothermal power station at Þeistareykir in the northeast of Iceland and is also expanding its hydropower station network in Búrfell, in the south of Iceland.
The offering of favourable long-term power purchase agreements makes Iceland a competitive location to set up data centers and the stable, cold climate of the country is particularly suitable for data center operations. Redundant submarine fibre cable system provides the reliable connectivity required by demanding international data centers.
Landsvirkjun has actively promoted Iceland to the responsible parties for determining future locations of data centers. The Company's website contains information on the benefits of Iceland in this regard:
http://www.landsvirkjun.com/datacenters
View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005221/en/
Contact:
Landsvirkjun
Magnús Þór Gylfason, +354 515 9000
Director of
Corporate Communications
Magnus.Thor.Gylfason@landsvirkjun.is
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom